SAN FRANCISCO — An everolimus-eluting bioresorbable scaffold was superior to angioplasty for the treatment of patients with chronic limb-threatening ischemia, according to the results of the LIFE-BTK trial presented at TCT 2023.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
